Published in BMJ on February 03, 1990
Methodologic quality and relevance of references in pharmaceutical advertisements in a Canadian medical journal. CMAJ (1994) 1.93
'The strategy of desire' and rational prescribing. Br J Clin Pharmacol (1994) 1.84
Quality of pharmaceutical advertisements in medical journals: a systematic review. PLoS One (2009) 1.58
Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry self-regulation. PLoS Med (2015) 1.47
Selling drugs to doctors--it's marketing, not education. Br J Gen Pract (2002) 1.12
Selling drugs to the public--should the UK follow the example of the US? Br J Gen Pract (2002) 1.11
Conflicts between commercial and scientific interests in pharmaceutical advertising for medical journals. Int J Health Serv (2003) 1.04
Misleading advertising for antidepressants in Sweden: a failure of pharmaceutical industry self-regulation. PLoS One (2013) 0.92
Commercial source of drug information: comparison between the United Kingdom and India. BMJ (1994) 0.75
An evaluation of drug promotional literatures published in scientific medical journals. J Pharm Bioallied Sci (2016) 0.75
National Scientific Medical Meeting. The Royal College of Physicians of Ireland. Dublin, 8-9 April 1994. Abstracts. Ir J Med Sci (1994) 0.75
Laboratory testing on cerebrospinal fluid. A reappraisal. Lancet (1987) 4.02
Information contained in drug advertisements. Br Med J (1975) 2.77
Medicines Act passes crucial test. Lancet (1988) 1.38
Racial and sexual discrimination in the selection of students for London medical schools. Med Educ (1986) 12.23
Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 5.36
Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet (1997) 2.66
Simplified method for measuring compliance of superficial veins. Cardiovasc Res (1971) 2.65
The rights of the patient in clinical research. Lancet (1988) 2.59
Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension (1995) 2.54
Management of a restricted drugs policy in hospital: the first five years' experience. Lancet (1985) 2.54
Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest (1992) 2.26
Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine. Proc Natl Acad Sci U S A (1990) 2.19
Vitamin B-6: food or medicine? The rules--and the politics--are different. BMJ (1998) 2.02
Nitric oxide synthesised from L-arginine mediates endothelium dependent dilatation in human veins in vivo. Cardiovasc Res (1989) 1.98
Paediatric prescribing: using unlicensed drugs and medicines outside their licensed indications. Br J Clin Pharmacol (1999) 1.96
Enalapril-induced cough. Lancet (1986) 1.86
Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens (1992) 1.77
Comparison of the pharmacokinetics of metronidazole in healthy female volunteers following either a single oral or intravenous dose. Br J Clin Pharmacol (1979) 1.76
Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol (1992) 1.51
Forearm blood flow responses to a nitric oxide synthase inhibitor in patients with treated essential hypertension. Cardiovasc Res (1994) 1.43
Observations on CEREBRAL HAEMORRHAGE DUE TO CAUSES OTHER THAN ARTERIOSCLEROSIS. Br Med J (1931) 1.41
Doctors and patients should sign prescriptions. BMJ (1998) 1.40
Drug company representatives and sales priorities. Lancet (1993) 1.39
Ethics committees. Wandsworth District Research Ethics Committee. Lancet (1996) 1.39
Questionnaire assessment of patients' attitudes and beliefs about asthma. Fam Pract (1986) 1.37
Predictors of mortality in hemodialysis patients. J Am Soc Nephrol (1993) 1.30
Distress and radiological investigations of the urinary tract in children. Eur J Pediatr (1996) 1.24
Nitric oxide and cardiovascular control. Exp Physiol (1993) 1.21
Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain. Hepatology (1992) 1.18
Second messenger role for NO widens to nervous and immune systems. Trends Pharmacol Sci (1989) 1.17
Acute erythroleukemia: evaluation of 48 cases with reference to classification, cell proliferation, cytogenetics, and prognosis. Am J Clin Pathol (1998) 1.14
The child with a non-blanching rash: how likely is meningococcal disease? Arch Dis Child (2001) 1.13
Interventions for the prevention and management of neck/upper extremity musculoskeletal conditions: a systematic review. Occup Environ Med (2006) 1.12
Endothelial "stunning" following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc Res (1996) 1.11
Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia. Clin Exp Immunol (2008) 1.11
Marital problems and sexual dysfunction: how are they related? Br J Psychiatry (1988) 1.07
Confusion over use of placebos in clinical trials. BMJ (1995) 1.05
A survey of suicidal behaviour in the Mid-Essex area in 1972. J R Coll Physicians Lond (1976) 1.02
Removal of metronidazole by haemodialysis. Br J Surg (1980) 1.00
Genetic epidemiological study of schizophrenia in Palau, Micronesia: prevalence and familiality. Am J Med Genet (1999) 1.00
Effect of HLA class II genotype on T helper lymphocyte responses and viral control in hepatitis C virus infection. J Viral Hepat (2001) 0.99
The reproducibility of endometrial volume acquisition and measurement with the VOCAL-imaging program. Ultrasound Obstet Gynecol (2002) 0.98
Local venous responses to endotoxin in humans. Circulation (1996) 0.98
Biology and clinical relevance of nitric oxide. BMJ (1994) 0.97
Relative potency and arteriovenous selectivity of nitrovasodilators on human blood vessels: an insight into the targeting of nitric oxide delivery. J Pharmacol Exp Ther (1995) 0.95
Economic evaluation alongside a phase II, multi-centre, randomised controlled trial of very early rehabilitation after stroke (AVERT). Cerebrovasc Dis (2008) 0.93
Dilator actions of arginine in human peripheral vasculature. Clin Sci (Lond) (1991) 0.93
Using multimedia for patient information--a program about nocturnal enuresis. Br J Urol (1998) 0.91
Injury prevention training: a cluster randomised controlled trial assessing its effect on the knowledge, attitudes, and practices of midwives and health visitors. Inj Prev (2004) 0.91
Parental involvement in paediatric cancer treatment decisions. Eur J Cancer Care (Engl) (2009) 0.91
Stability indicating validated HPLC method for quantification of levothyroxine with eight degradation peaks in the presence of excipients. Int J Pharm (2008) 0.91
Comparison of lignocaine-prilocaine cream and amethocaine gel for local analgesia before venepuncture in children. Acta Paediatr (1999) 0.89
Endothelium-derived relaxing factor is an endogenous vasodilator in man. Br J Pharmacol (1989) 0.88
Potent antitumour activity of a new class of tumour-specific killer cells. Nature (1997) 0.88
The pharmaceutical price regulation scheme: a time for change. Lancet (1985) 0.87
Carcinoma of the OEsophagus. Results of Deep X-Ray Treatment. Proc R Soc Med (1941) 0.86
Physiological importance of nitric oxide. BMJ (1991) 0.86
Oral infection of weanling foals with an equine isolate of Lawsonia intracellularis, agent of equine proliferative enteropathy. J Vet Intern Med (2010) 0.86
Vascular and hormonal responses to arginine: provision of substrate for nitric oxide or non-specific effect? Clin Sci (Lond) (1995) 0.85
Vasodilatation to arachidonic acid in humans. An insight into endogenous prostanoids and effects of aspirin. Circulation (1995) 0.85
Penicillin and tetracycline sensitivity of Jamaican strains of gonococci. West Indian Med J (1974) 0.85
Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma. BMC Cancer (2012) 0.85
Defective repair of O6-methylguanine-DNA in primary Sjögren's syndrome patients predisposed to lymphoma. Ann Rheum Dis (1995) 0.84
Two cases of ethambutol nephrotoxicity. Br Med J (1976) 0.83
Prealbumin and lipoprotein(a) in hemodialysis: relationships with patient and vascular access survival. Am J Kidney Dis (1993) 0.82
The vascular endothelium in diabetes and hypertension. J Hypertens Suppl (1992) 0.82
The Clinical History and Morbid Anatomy of a Case of Generalized Sclerodermia with Severe Muscular Atrophy. Proc R Soc Med (1913) 0.82
alpha-Tocopherol concentrations in equine serum and cerebrospinal fluid after vitamin E supplementation. Vet Rec (2010) 0.81
Stored blood transfusion induces transient pulmonary arterial hypertension without impairing coagulation in an ovine model of nontraumatic haemorrhage. Vox Sang (2013) 0.81
Characterization of hepatic nitric oxide synthase: identification as the cytokine-inducible form primarily regulated by oxidants. Mol Pharmacol (1996) 0.81
Holding children still for procedures. Paediatr Nurs (1997) 0.81
Enzymatic hydrolysis of cellulose dissolved in N-methyl morpholine oxide/water solutions. Bioresour Technol (2009) 0.80
Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens (1993) 0.80
Gastric intramural pH in mechanically ventilated patients. Thorax (1996) 0.80
A multicentre comparison of clindamycin and metronidazole in the treatment of anaerobic infections. Scand J Infect Dis Suppl (1981) 0.79
Nucleotide sequence of the trout metallothionein A gene 5' regulatory region. Nucleic Acids Res (1990) 0.79
Bedwetting, behaviour and self-esteem: a review of the literature. Child Care Health Dev (2001) 0.79
Development of a novel large bandwidth front-end system for high peak power OPCPA systems. Opt Express (2011) 0.78
The effect of endothelium-derived nitric oxide on ex vivo whole blood platelet aggregation in man. Eur J Clin Pharmacol (1992) 0.78
A comparison of metronidazole and clindamycin for the treatment of intra-abdominal anaerobic infection: a multicentre trial. J Antimicrob Chemother (1982) 0.78
Multimedia versus written information for nocturnal enuresis education: a cluster randomized controlled trial. Child Care Health Dev (2003) 0.78
Aldose reductase inhibitors in clinical practice. Preliminary studies on diabetic neuropathy and retinopathy. Drugs (1986) 0.78
Drugs and breast-feeding. Br Med J (1979) 0.78
Effects of administration of an avirulent live vaccine of Lawsonia intracellularis on mares and foals. Vet Rec (2009) 0.78
Two cases of tropical pyomyositis of the sternocleidomastoid muscle occurring in the UK. Br J Oral Maxillofac Surg (2009) 0.77
Effect of acute plasma volume expansion on peripheral arteriolar tone in healthy subjects. Clin Sci (Lond) (1992) 0.77
Monoclonal antibodies to avian paramyxovirus type 2. Avian Pathol (1990) 0.77
Clinical experience with sorbinil--an aldose reductase inhibitor. Metabolism (1986) 0.77
Illegibility of drug advertisements. Lancet (1984) 0.76
Nitric oxide and the control of human vascular tone in health and disease. Eur J Med (1993) 0.76
Moclobemide in the treatment of major depressive disorder (DSM-3) following traumatic brain injury. Brain Inj (1999) 0.76
Construction and expression of plasmids containing mutated diphtheria toxin A-chain-coding sequences. Infect Immun (1991) 0.76
Misleading advertisements: sanctions and corrections. Lancet (1984) 0.76
Drugs in sport: a counsel of perfection thwarted by reality. Br Med J (Clin Res Ed) (1988) 0.75
Patients' rights. Lancet (1994) 0.75
Dornase alfa for cystic fibrosis. Evidence supporting use of this drug has not yet been published. BMJ (1995) 0.75
Dornase-alfa and orphan drugs. Lancet (1995) 0.75
Changes in peripheral venous compliance after myocardial infarction. Cardiovasc Res (1972) 0.75
Drug and Therapeutics Bulletin defends its stance over donepezil. BMJ (1998) 0.75
Volunteering for research. Lancet (1992) 0.75
EMEA and consumer representation. European Medicines Evaluation Agency. Lancet (1997) 0.75